Diabetes Prevention in the Vitamin D and Omega-3 Trial

Emerging evidence suggests favorable effects of both vitamin D and marine omega-3 fatty acids on glucose homeostasis. Optimal vitamin D intake is essential for insulin secretion and action, and omega-3 fatty acids may reduce diabetes risk as a result of favorable effects on insulin sensitivity, endothelial function, chronic inflammation, or other metabolic abnormalities. Although the metabolic effects of vitamin D and omega-3 fatty acids show considerable promise for the primary prevention of type 2 diabetes (T2D), there are no completed, ongoing, or planned randomized clinical trials of vitamin D or omega-3 supplements that include T2D as a primary outcome in a general population.

We thus propose to utilize an NIH-funded randomized trial (1 U01 CA138962) to test the hypothesis that vitamin D and omega-3 supplementation will reduce the risk of T2D. We will further assess whether and to what extent vitamin D or omega-3 supplementation will improve insulin sensitivity and pancreatic beta-cell function in a subsample of the trial cohort. The VITamin D and OmegA-3 TriaL (VITAL) is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the benefits and risks of vitamin D3 (2,000 IU/day) and marine omega-3 fatty acid (eicosapentaenoic acid [EPA] + docosahexaenoic acid [DHA], 1g/day) supplements in the primary prevention of cancer and cardiovascular disease (CVD). The VITAL trial will aim to enroll 20,000 men and women (aged ≥50 and ≥55 years, respectively). The planned treatment duration is 5 years after a 1.5-year recruitment period. This diabetes ancillary study aims to implement an inexpensive and efficient strategy to validate self-reported incident T2D cases in the entire trial population and to collect pre- and post-intervention measures of glucose, insulin, and hemoglobin A1c (HbA1c) in a subset of participants. Two methods of diabetes case validation are proposed. First, we plan to collect detailed information about diagnostic glucose testing and anti-diabetic medication use from medical records and/or supplementary questionnaires completed by the participant's physician. Second, to complement our diabetes ascertainment process, we will also plan to retrieve additional data on diabetes diagnoses and hypoglycemic medications by linking the participants with the Centers for Medicare and Medicaid Services (CMS) database. In addition to evaluating whether the study interventions impact the onset of clinical diabetes, we propose to collect pre- and post-intervention measures of glucose, insulin, and HbA1c in a subset of the participants to reliably assess whether vitamin D or omega-3 supplementation alters insulin and glucose homeostasis. We plan to recruit 1,000 participants without prior clinical diabetes at the Clinical and Translational Science Center (CTSC) site at Brigham and Women's Hospital. A standard 2-hour oral glucose tolerance test (OGTT) and HbA1c measurements will be performed during the CTSC visits at baseline and at 2-year post-randomization.

Primary Aims:

1. To test whether vitamin D3 and/or EPA+DHA supplementation reduces the risk of T2D among all initially non-diabetic participants in the VITAL trial.
2. To test whether vitamin D3 and/or EPA+DHA supplementation improves insulin sensitivity and beta-cell function in a subset of 1,000 non-diabetic participants receiving OGTT at baseline and 2-year post-randomization.

Secondary Aims: